Stockscreener 앱 받기
45.82
0.17%
0.08
시장 영업 전:
46.00
0.18
+0.39%
전일 마감가:
$45.74
열려 있는:
$45.92
하루 거래량:
1.22M
Relative Volume:
1.10
시가총액:
$5.41B
수익:
$3.22M
순이익/손실:
$-576.40M
주가수익비율:
-8.5167
EPS:
-5.38
순현금흐름:
$-407.05M
1주 성능:
+1.30%
1개월 성능:
-6.24%
6개월 성능:
-18.77%
1년 성능:
-43.40%
1일 변동 폭
$45.26
$46.32
1주일 범위
$45.26
$48.45
52주 변동 폭
$44.49
$84.92
Cytokinetics Inc Stock (CYTK) Company Profile
명칭
Cytokinetics Inc
전화
(650) 624-3000
주소
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
CYTK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
45.82 | 5.41B | 3.22M | -576.40M | -407.05M | -5.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-08 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-07 | 개시 | B. Riley Securities | Buy |
| 2023-08-15 | 개시 | SVB Securities | Outperform |
| 2023-02-17 | 개시 | BofA Securities | Neutral |
| 2022-12-23 | 재확인 | Needham | Buy |
| 2022-12-20 | 개시 | Truist | Buy |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-01-28 | 개시 | Goldman | Buy |
| 2021-12-22 | 개시 | Oppenheimer | Outperform |
| 2021-12-10 | 개시 | JP Morgan | Overweight |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2021-02-18 | 개시 | Barclays | Overweight |
| 2021-01-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-29 | 개시 | Goldman | Neutral |
| 2020-07-10 | 개시 | Raymond James | Strong Buy |
| 2020-05-05 | 개시 | Mizuho | Buy |
| 2020-04-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 재개 | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 재확인 | Morgan Stanley | Overweight |
| 2017-11-22 | 다운그레이드 | Needham | Strong Buy → Buy |
| 2017-11-21 | 재확인 | H.C. Wainwright | Buy |
| 2017-07-31 | 개시 | Morgan Stanley | Overweight |
| 2017-03-08 | 개시 | Rodman & Renshaw | Buy |
| 2017-02-06 | 업그레이드 | Needham | Buy → Strong Buy |
| 2016-12-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 재확인 | Needham | Buy |
| 2015-11-10 | 재확인 | FBR Capital | Outperform |
| 2015-11-09 | 재확인 | ROTH Capital | Buy |
| 2015-07-24 | 재확인 | MLV & Co | Buy |
| 2014-12-31 | 재확인 | ROTH Capital | Buy |
| 2014-11-04 | 업그레이드 | MLV & Co | Hold → Buy |
| 2014-04-28 | 재확인 | Needham | Buy |
모두보기
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
Cantor Fitzgerald Forecasts Cytokinetics FY2025 Earnings - MarketBeat
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Stifel starts Cytokinetics stock with Buy, $80 target - MSN
Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus.com
Cytokinetics' (CYTK) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction - Yahoo Finance
Cytokinetics' SWOT analysis: aficamten's potential drives stock outlook - Investing.com
Cytokinetics' SWOT analysis: aficamten's potential drives stock outlook By Investing.com - Investing.com Canada
Cytokinetics (NASDAQ:CYTK) Given "Market Outperform" Rating at JMP Securities - MarketBeat
S&P 500 Futures Rise in Premarket Trading; Trump Media & Tech, Cytokinetics Lag - Barron's
Cytokinetics Announces 2025 Corporate Milestones and Vision 2030 - GlobeNewswire
Cytokinetics Sets FDA Review Date for Aficamten, Unveils Ambitious 2030 Global Expansion Plan - StockTitan
HC Wainwright Reiterates “Buy” Rating for Cytokinetics (NASDAQ:CYTK) - Defense World
Cytokinetics EVP sells shares worth $98,640 By Investing.com - Investing.com South Africa
Cytokinetics EVP sells shares worth $98,640 - Investing.com India
Cytokinetics (NASDAQ:CYTK) Sets New 1-Year LowTime to Sell? - MarketBeat
Insider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells 2,000 Shares of Stock - MarketBeat
Cytokinetics (NASDAQ:CYTK) Receives Buy Rating from HC Wainwright - MarketBeat
Cytokinetics stock hits 52-week low at $45.59 amid market challenges - Investing.com Canada
Vanguard Group Inc's Strategic Acquisition of Cytokinetics Inc S - GuruFocus.com
Cytokinetics’ SWOT analysis: aficamten progress boosts stock outlook By Investing.com - Investing.com Nigeria
Cytokinetics' SWOT analysis: aficamten progress boosts stock outlook - Investing.com
Cytokinetics' SWOT analysis: aficamten progress boosts stock outlook By Investing.com - Investing.com Canada
Congestive Heart Failure Market Expected to rise, 2034 | Novartis, Boehringer Ingelheim, Eli Lilly, Bayer, Merck, AstraZeneca, Amgen, Otsuka Pharmaceutical, Cytokinetics, Mesoblast, Novo Nordisk - Barchart
Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Cytokinetics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
10 Clinical Trials Of 2024 – Hits, Misses And Some In Between - News & Insights
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Cytokinetics Awards Stock Grants to New Employees, Including Options and Performance Units - StockTitan
Nvidia Corp (NVDA-Q) QuotePress Release - The Globe and Mail
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Sold by Principal Financial Group Inc. - MarketBeat
S&P 500 Futures Drop in Premarket Trading; Sportradar Group, Cytokinetics Lead - MarketWatch
Cytokinetics Initiates Confirmatory Study on Heart Failure Drug - MSN
Cytokinetics' aficamten application validated by EU regulators - MSN
Cytokinetics' potential blockbuster heart drug flips to new partner in China - The Business Journals
Cytokinetics' Heart Drug Aficamten Advances with EMA Validation for Key European Review - StockTitan
Cytokinetics, Incorporated Announces Executive Changes - Marketscreener.com
Cytokinetics (CYTK) Stock Rises on New Licensing Deal - GuruFocus.com
Why Cytokinetics Stock Was a Nearly 5% Winner Today - MSN
Spinal Muscular Atrophy Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and MOA, ROA by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme Corp - The Globe and Mail
Cytokinetics stock rises on Sanofi's rights acquisition By Investing.com - Investing.com Canada
HC Wainwright Reiterates "Buy" Rating for Cytokinetics (NASDAQ:CYTK) - MarketBeat
Sanofi: acquisition of aficamten rights for China - Marketscreener.com
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China - The Manila Times
Cytokinetics, Incorporated Announces Sanofi Acquires Exclusive Rights to Develop and Commercialize Aficamten from Corxel Pharmaceuticals - Marketscreener.com
Calculating The Fair Value Of Cytokinetics, Incorporated (NASDAQ:CYTK) - Yahoo Finance
Franklin Resources Inc. Sells 1,820,114 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics (NASDAQ:CYTK) Price Target Raised to $82.00 - MarketBeat
Cytokinetics CFO to assume additional role after officer departs By Investing.com - Investing.com Australia
Cytokinetics Inc (CYTK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):